Fate Therapeutics FATE 深 沪
已收盘 08-21 16:00:00 美东时间
2.33
-0.120
-4.90%
华盛通- 最 高2.508
- 今 开2.46
- 成交量 169.66万股
- 最 低 2.32
- 昨 收 2.45
- 总市值 2.79亿
- 52周最高 3.23
- 市盈率 静 --
- 换手率 1.42%
- 52周最低 0.9335
- 委 比 -52.88%
- 总股本 1.20亿
- 历史最高 121.16
- 量 比 0.95
- 振 幅 7.67%
- 历史最低 0.6611
- 每 手 1
- 风险率 0.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
Fate Therapeutics Highlights Initiation Of And Treatment Of First Patient In RECLAIM-LN, Phase 2 Potentially Registrational Clinical Trial Of FT819 In Patients With Refractory Moderate-To-Severe SLE With Lupus Nephritis
First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated regulatory pathway supported by RMAT designation and participation in the FDA CMC Development and Readin...
08-14 19:05
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
Fate Therapeutics has initiated its Phase 2 RECLAIM-LN trial of FT819, an off-the-shelf CAR T-cell therapy, for patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis. The trial aims to enroll approximately 53 patients and assess the proportion achieving complete renal response at Week 26. FT819 is derived from induced pluripotent stem cells (iPSCs), offering a scalable, cost-effective, and readily ava...
08-14 11:00
Fate Therapeutics Q2 EPS $(0.25) Beats $(0.27) Estimate, Sales $2.082M Beat $1.366M Estimate
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 13.79 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $2.082 millio...
08-13 20:55
Phoenix Education Partners, Pentair And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures were mostly higher this morning, with the Nasdaq 100 futures gaining around 100 points on Wednesday. Shares of Phoenix Education Partners Inc (NYSE:PXED) fell sharply in pre-market trading after the company reported third-quarter financial results and cut its FY26 sales guidance b...
07-15 20:02
Fate Therapeutics To Demonstrate Data On Its CAR T-cell Product Candidate FT819 At International Society For Stem Cell Research 2026 Annual Meeting
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune disease, today announced that preliminary clinical...
07-06 20:43
美股大行评级 | 存储再获看多！美光、闪迪、西部数据获机构上调目标价；次新股Cerebras、Blackstone、EagleRock获多家机构首予买入平均
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.25美元升至5.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9美元升至9.25美元
06-09 11:33
Fate Therapeutics shares are trading lower. The company presented clinical data this weekend featuring its off-the-shelf CAR T-cell program FT836 at ASCO Annual Meeting.
Fate Therapeutics shares are trading lower. The company presented clinical data...
06-01 23:05
Fate Therapeutics To Feature Data From Off-The-Shelf CAR T-Cell Programs At 2026 ASCO And EULAR Annual Meetings
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with
05-21 20:34
Fate Therapeutics Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $1.299M Beat $1.139M Estimate
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 18.75 percent increase over losses of $(0.32) per share from
05-13 20:33
